Racial inequities are well-documented across the gynecologic oncology care continuum,
including the representation of racial and ethnic minoritized groups (REMGs) in gynecologic …

Objectives It is important to develop effective therapies in minorities to ensure equity in
cancer care. Underrepresentation of minorities in early phase trials may cause therapies that …

Objective Participation of minority populations in clinical trials is paramount to understanding
and overcoming cancer racial disparities. The goal of this project is to evaluate minority …

OBJECTIVE: To characterize whether enrollment patterns in precision oncology clinical trials
for gynecologic cancers reflect the racial and ethnic diversity of patients with gynecologic …

Importance Racial and ethnic disparities in clinical trial enrollment are unjust and hinder
development of new cancer treatments. Objective To examine the association of race and …

A commitment to representative and equitable enrollment of marginalized populations in
clinical trials is a shared value of all who are dedicated to high quality clinical research and …

Purpose Clinical trials advance the standard of care for patients. Patients enrolled in trials
should represent the population who would benefit from the intervention in clinical practice …

Racial and ethnic diversity has historically been difficult to achieve in National Cancer
Institute–sponsored clinical trials, even while as many as 80% of those trials have faced …

Objectives Given the disparity that exists in enrollment of minorities to oncology clinical trials,
the objective of our study was to assess whether race is associated with willingness to …

Objective To describe the participation of minority women in clinical trials using immunologic
agents for breast and gynecologic cancers. Methods A retrospective review of completed …